Ascendis Pharma A/S ADR [ASND] stock is trading at $186.59, up 1.33%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ASND shares have gain 14.25% over the last week, with a monthly amount glided 6.03%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Morgan Stanley upgraded its rating to Overweight on May 05, 2025, and kept the price target unchanged to $250. On April 16, 2025, RBC Capital Mkts initiated with a Outperform rating and assigned a price target of $205 on the stock. UBS started tracking the stock assigning a Buy rating and suggested a price target of $196 on January 07, 2025. Oppenheimer upgraded its rating to a Outperform but $180 remained the price target by the analyst firm on September 05, 2024. TD Cowen upgraded its rating to Buy for this stock on June 25, 2024, and upped its price target to $175. In a note dated May 31, 2024, Stifel initiated an Buy rating and provided a target price of $200 on this stock.
Ascendis Pharma A/S ADR [ASND] stock has fluctuated between $111.09 and $184.78 over the past year. Currently, Wall Street analysts expect the stock to reach $180 within the next 12 months. Ascendis Pharma A/S ADR [NASDAQ: ASND] shares were valued at $186.59 at the most recent close of the market. An investor can expect a potential drop of -3.53% based on the average ASND price forecast.
Analyzing the ASND fundamentals
Ascendis Pharma A/S ADR [NASDAQ:ASND] reported sales of 394.05M for the trailing twelve months, which represents a growth of 2.09%. Gross Profit Margin for this corporation currently stands at 0.85% with Operating Profit Margin at -0.91%, Pretax Profit Margin comes in at -0.92%, and Net Profit Margin reading is -0.93%. To continue investigating profitability, this company’s Return on Assets is posted at -0.32, Equity is 1.91 and Total Capital is -1.9. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -4.46.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Ascendis Pharma A/S ADR’s Current Ratio is 1.04. Further, the Quick Ratio stands at 0.71, while the Cash Ratio is 0.58. Considering the valuation of this stock, the price to sales ratio is 28.59.
Transactions by insiders
Recent insider trading involved Shu Aimee, Officer, that happened on May 12 ’25 when 2018.0 shares were purchased. Officer, JENSEN FLEMMING STEEN completed a deal on May 07 ’25 to buy 10938.0 shares. Meanwhile, Officer Shu Aimee bought 4204.0 shares on May 06 ’25.
